araag2/HINT huggingface dataset:
Clinical trial NCT01084876 (phase 3, status: unknown status)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ct-p6, herceptin, paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Are females

          -  Have a Her 2 over-expression

          -  Have ECOG 0 or 1

        Exclusion Criteria:

          -  Current clinical or radiographic evidence CNS metastases

          -  Current Known infection

          -  Pregnant or nursing mother
Clinical trial NCT00003644 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial cancer of one of the following histologic
             cell types:

               -  Serous adenocarcinoma

               -  Malignant Brenner's tumor

               -  Mucinous adenocarcinoma

               -  Endometrioid

               -  Adenocarcinoma

               -  Clear cell adenocarcinoma

               -  Undifferentiated carcinoma

               -  Transitional cell

               -  Mixed epithelial carcinoma

               -  Adenocarcinoma - not otherwise specified

          -  Meets 1 of the following criteria:

               -  Stage Ia or Ib, grade 3 or clear cell

               -  Stage Ic or II, all grades/histologies

          -  Complete surgical staging

          -  No tumors of low malignant potential (borderline tumors)

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  GOG 0-3

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 times normal

          -  Alkaline phosphatase no greater than 3 times normal

          -  SGOT no greater than 3 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Other:

          -  No other invasive malignancies within the past 5 years except nonmelanoma skin cancer

          -  No major systemic medical illness expected to affect survival

          -  Body surface area no greater than 2.0

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No prior treatment for this malignancy except surgical staging

          -  No prior anticancer therapy that would preclude study participation
Clinical trial NCT00226915 (phase 3, status: completed)
Conditions: epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer
ICD codes: H18.523, H18.521, H18.522, H18.529, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02, C57.00, C57.01, C57.02
Drugs: paclitaxel+carboplatin, paclitaxel+carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed stage II-IV ovarian epithelial, primary peritoneal, or
             fallopian tube cancer

          -  No prior chemotherapy

          -  Age: 20 and more

          -  Performance status: ECOG 0-3

          -  1) Absolute neutrophil count at least 1,500/mm3 2) Platelet count at least 100,000/mm3
             3) Bilirubin less than 1.5mg/dL 4) SGOT less than 100 IU/l 5) Serum creatinine less
             than 1.5mg/dL

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with ovarian borderline tumor

          -  Patients who have any evidence of the other cancer present within the last 5 years
             with the exception of carcinoma in situ or intramucosal cancer that is curable with
             local therapy

          -  Patients with active infection or uncontrolled diabetes

          -  Patients with unstable angina, or those who have had a myocardial infarction within
             the past 6 months, or patients with serious arrythmia that requires medication

          -  Patients who have a history of hypersensitivity to polyoxyethylated castor oil
             (Cremophor EL)
Clinical trial NCT01272193 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis

          -  Body Mass Index (BMI) below or equal to 35.0 kg/m^2

          -  Insulin naive subject and ongoing treatment with 1 or more oral antidiabetic drugs
             (OADs) for at least 12 weeks prior to randomisation with at least recommended
             maintenance dose according to local, approved labelling Allowed are: a. Previous short
             term insulin treatment up to 14 days; b. Treatment during hospitalization or during
             gestational diabetes is allowed for periods longer than 14 days)

        Exclusion Criteria:

          -  Anticipated change in concomitant medication known to interfere significantly with
             glucose metabolism, such as systemic corticosteroids, beta-blockers, mono amino
             oxidase (MAO) inhibitors

          -  Use of glucagon-like peptide-1 (GLP-1) receptor agonists, buformine and/or
             rosiglitazone within the last 12 weeks prior to randomisation

          -  Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty
Clinical trial NCT02733419 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: enfuvirtide, optimized background antiretroviral regimen (ob)
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O, CCO
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with HIV-1 infection

          -  Female participants without any risk of pregnancy

          -  Participants previously treated with drugs of 2 or 3 different antiretroviral classes

          -  Participants currently on highly active antiretroviral treatment (HAART) for more than
             4 weeks and with a plasma viral load between 1,000 and 300,000 copies of HIV-1
             ribonucleic acid per milliliter (RNA/mL)

          -  Participants with the possibility of potentially effective OB without enfuvirtide,
             consisting to 2 to 5 drugs, at least two of which are active from at least two
             different antiretroviral classes

          -  Cluster of differentiation 4 (CD4) cell count greater than (>) 50 cells/cubic
             millimeter (mm^3) at screening

          -  Participants in whom resistance mutations have been detected in reverse transcriptase
             and/or protease genes

          -  Enfuvirtide-naive participants

        Exclusion Criteria:

          -  Women of childbearing age not using effective mechanical contraception

          -  Pregnant or breastfeeding women

          -  Presence of HIV-2 coinfection

          -  Participants participating or having participated to another clinical trial during the
             30 days prior to selection for this trial

          -  Participants having previously been treated with enfuvirtide

          -  Presence active opportunistic infection within 1 month of study entry

          -  Existence of Grade 4 clinical or laboratory abnormalities

          -  Cirrhosis or severe hepatic failure

          -  Uncontrolled diabetes or requiring insulin

          -  Consumption of alcohol and/or narcotics and/or other substances
Clinical trial NCT00623805 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥ 18 years of age.

          -  Histologically confirmed colon or rectal cancer, with unresectable metastatic disease.

          -  At least 1 measurable lesion.

          -  Outpatient, with Eastern Cooperative Oncology Group (ECOG) Performance Status = 0-1.

        Exclusion Criteria:

          -  Previous treatment with Avastin.

          -  Previous systemic treatment for advanced or metastatic disease.

          -  clinically significant cardiovascular disease.

          -  Daily chronic treatment with high doses of aspirin (> 325 mg/day) or non-steroidal
             anti-inflammatory drugs.
Clinical trial NCT00477282 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: karenitecin, topotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C(CC[Si](C)(C)C)C4=CC=CC=C4N=C13)C2=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Confirmed diagnosis of stage III or IV epithelial ovarian cancer

          -  Have cancer that is resistant to platinum/taxane-based chemotherapy regimens

          -  Have measurable, progressive disease

          -  Have an ECOG PS ≤ 2

        Exclusion Criteria:

          -  Have uncontrolled high blood pressure, uncontrolled diabetes mellitus, or other
             serious underlying medical condition not compatible with study entry.

          -  Have a life expectancy < 3 months

          -  Received prior treatment with a camptothecin (topotecan, CPT-11, or investigational
             camptothecins).

          -  Received prior treatment with any platinum agent other than cisplatin or carboplatin.

          -  Received prior radiation therapy to greater than one-third of the hematopoietic sites
             (one-third of the pelvis and axial skeleton combined).
Clinical trial NCT01461369 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: diclofenac, diclofenac, placebo
SMILES: OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl, OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of Functional Class I-III OA of the hip or knee with documented
             osteoarthritis flare at baseline

          -  Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for
             OA pain

          -  Discontinued all analgesic therapy at Screening

          -  For women of child-bearing potential: a woman who is not pregnant and not nursing, and
             who is practicing an acceptable method of birth control

        Exclusion Criteria:

          -  History of allergic reaction or clinically significant intolerance to acetaminophen,
             aspirin, or any NSAIDS, including diclofenac

          -  Requires continuous use of opioid or opioid combination products to control OA pain of
             the knee or hip

          -  Clinically significant unstable cardiac, respiratory, neurological, immunological,
             hematological, or renal disease

          -  Significant difficulties swallowing capsules or unable to tolerate oral medication

          -  Previous participation in another clinical study of Diclofenac Capsules or received
             any investigational drug or device or investigational therapy within 30 days before
             Screening.
Clinical trial NCT00225186 (phase 3, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: visanne (sh t00660aa , bay86-5258)
SMILES: [H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients with endometriosis-associated pelvic pain

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  History or suspicion of hormone dependent tumor

          -  Therapy resistant endometriosis or need for primary surgical treatment

          -  Any other conditions which forbid the participation
Clinical trial NCT00556959 (phase 3, status: completed)
Conditions: attention deficit disorder with hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: high dose clonidine hcl sustained release, low dose clonidine hcl sustained release, placebo
SMILES: ClC1=CC=CC(Cl)=C1NC1=NCCN1, ClC1=CC=CC(Cl)=C1NC1=NCCN1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female between 6 and 17 years of age, inclusive

          -  Diagnosis of ADHD of the hyperactive or combined inattentive/hyperactive subtypes
             according to DSM-IV criteria

          -  Minimum score of 26 on the ADHDRS-IV questionnaire at Baseline

          -  General good health as judged by the Principal Investigator

          -  Body mass index ≥ 5th percentile of the subject's age group according to the CDC
             growth chart.

          -  Ability to swallow tablets

          -  General IQ ≥80 as judged by the Principal Investigator

          -  Subject as well as parent/guardian able to sign informed assent or consent form.

        Exclusion Criteria:

          -  If female of child-bearing potential, pregnant or lactating or does not agree to use a
             medically acceptable form of birth control, such as hormonal medication,
             double-barrier method, or IUD

          -  Presence of a clinically significant illness or abnormality on physical examination or
             clinical laboratory evaluations that, in the opinion of the investigator, would
             increase the safety risks from clonidine administration or interfere with the ability
             of the patient to take part in the study.

          -  Presence of clinically significant abnormality on centrally interpreted
             Electrocardiogram (ECG) readings

          -  History or presence of a concomitant psychiatric disorder requiring psychotropic
             medication or a severe concomitant Axis I or Axis II disorder that could interfere
             with study assessments in the judgment of the Principal Investigator

          -  History of concomitant conduct disorder (CD)

          -  History of seizures, except for a single episode of febrile seizure prior to age 2

          -  History of syncopal episodes

          -  Presence of a disorder that would interfere with the absorption, metabolism, or
             excretion of clonidine

          -  History of intolerance to clonidine, including any dermatologic reaction to
             transdermal clonidine

          -  Presence or history of alcohol or drug abuse

          -  Positive drug screen, with the exception of ADHD drugs

          -  Use of any investigational drug within 30 days of study start.
Clinical trial NCT00163449 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ciclesonide, placebo
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Written informed consent by the parents or legal guardians of the patient

          -  Outpatients

          -  Good health with the exception of asthma

          -  Documented diagnosis of asthma for more than 6 months

          -  Use of rescue medication only or pretreatment with a controller drug

        Main Exclusion Criteria:

          -  Concomitant severe diseases

          -  Diseases contraindicated for the use of inhaled steroids

          -  Other relevant lung diseases causing impairment in pulmonary function

          -  Recurrent, episodic wheezing only

          -  History of life-threatening asthma

          -  History of any mechanical ventilation

          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical evaluation

          -  Premature birth (< 32 weeks gestation)
Clinical trial NCT00594568 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: ly450139, placebo
SMILES: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=CC=CC=C2CCN(C)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets criteria for mild to moderate Alzheimer's disease (AD) with Mini-Mental State
             Examination (MMSE) score of 16-26 at Visit 1

          -  Modified Hachinski Ischemia Scale score of less than or equal to 4

          -  Geriatric Depression Scale score of less than or equal to 6

          -  A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2
             years with no findings inconsistent with a diagnosis of AD

          -  If female, must be without menstruation for at least 12 consecutive months or have had
             both ovaries removed

        Exclusion Criteria:

          -  Is not capable of swallowing whole oral medication

          -  Has serious or unstable illnesses

          -  Does not have a reliable caregiver

          -  Chronic alcohol or drug abuse within the past 5 years

          -  Has ever had active vaccination for AD
Clinical trial NCT00363857 (phase 3, status: completed)
Conditions: restless legs syndrome (rls), restless legs syndrome
ICD codes: G25.81, R45.1, G25.81
Drugs: ropinirole
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Patients diagnosed with Restless Legs Syndrome (RLS) with symptoms such as:
             uncomfortable or "creepy-crawly" sensations in your legs, overwhelming urge to move
             your legs to relieve these sensations, sensations go away when you move your legs, or
             trouble falling asleep or staying asleep because of these symptoms.

          -  Patients must give written informed consent prior to any specific study procedures.

        Exclusion criteria:

          -  Patients who suffer from narcolepsy, sleep terror disorder, sleepwalking disorder, or
             a breathing related sleep disorder.

          -  Patients diagnosed with renal failure (end-stage renal disease) iron deficient anemia
             or pregnancy.

          -  Patients suffering from other movement disorders (i.e. Parkinson's Disease).

          -  Patients who have medical conditions such as diabetes, peripheral neuropathy,
             rheumatoid arthritis, or fibromyalgia syndrome.

          -  Participation in any clinical drug or device trial in the last three months.

        Other inclusion or exclusion criteria to be evaluated by the physician.
Clinical trial NCT01204853 (phase 3, status: terminated)
Conditions: hypertension, pulmonary
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: sitaxentan
SMILES: CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl
Reason stopped: 
    safety issue: the trial was prematurely terminated on dec 9, 2010, due to safety concerns,
    specifically new emerging evidence of hepatic injury.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Has a current diagnosis of symptomatic PAH

          -  Has 6MWT distances from 150 to 450 meters and distance

        Exclusion Criteria:

          -  Previous exposure to an endothelin receptor antagonist

          -  Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure
             >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening.

          -  Has hypotension defined as systolic arterial pressure <90 mm Hg after sitting for 5
             minutes at Screening.
Clinical trial NCT00654706 (phase 3, status: completed)
Conditions: schizophrenia, cognition
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: sertindole, quetiapine
SMILES: FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of schizophrenia

          -  Man or woman, aged between 18 and 55 years

        Exclusion Criteria:

          -  Current Axis I primary psychiatric diagnosis other than schizophrenia

          -  Not previously received antipsychotic drugs for schizophrenia

          -  Acute exacerbation requiring hospitalisation within the last 3 months

          -  Clinically significant extrapyramidal symptoms

          -  Clinically significant cardiovascular disease, congestive heart failure, cardiac
             hypertrophy, arrhythmia or bradycardia

          -  Congenital long QT syndrome or a family history of this disease, or known acquired QT
             interval prolongation

          -  Significant ECG abnormalities

          -  Hypokalaemia or hypomagnesaemia

          -  In concurrent treatment with drugs inhibiting the P450 enzymes system CYP3A
Clinical trial NCT00626288 (phase 3, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: mesalazine, placebo
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  IBS patients with positive diagnosis inclosing Rome III criteria

        Exclusion Criteria:

          -  Any organic or metabolic disease